Ironwood Pharmaceuticals, Inc., was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, a S&P SmallCap 600 company, is a leading gastrointestinal (GI) healthcare company with a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They are pioneers in the development of LINZESS (linaclotide), the market leader in branded prescriptions in the United States, for the treatment of adult irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC) with constipation.
